Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

Mark A. Marzinke, Brett Hanscom, Zhe Wang, Steven A. Safren, Christina Psaros, Deborah Donnell, Paul A. Richardson, Philip A. Sullivan, Susan H. Eshleman, Andrea Jennings, Kailazarid Gomez Feliciano, Emília M. Jalil, Carolina Coutinho, Nadir Cardozo, Bernardo Maia, Taimur Khan, Yashna Singh, Keren Middelkoop, Julie Franks, Javier Valencia, Naiymah Sanchez, Jonathan Lucas, James F. Rooney, Alex R. Rinehart, Susan L. Ford, Adeola Adeyeye, Myron S. Cohen, Marybeth McCauley, Raphael J. Landovitz, Beatriz Grinsztejn, Suwat Chariyalertsak, Chaiwat Ungsedhapand, Nittaya Phanuphak, Trần Việt Hà, María Inés Figueroa, Marcelo Losso, Esper G. Kallás, José Valdez Madruga, Breno Santos, Beatriz Grinsztejn, Juan Carlos Hinojosa Boyer, Milagros Erika Matta Aguirre, Jorge A. Gallardo-Cartagena, Javier Valencia, Y.P. Ramirez, Keren Middelkoop, Paul Goepfert, Sybil Hosek, Albert Liu, Jessica Justman, Christopher B. Hurt, Daniel Reirden, Carl J. Fichtenbaum, Christopher Hall, Kenneth H. Mayer, Manya Magnus, Cornelius Van Dam, Julie Franks, Colleen F. Kelley, Roberto C. Arduino, Anne Rompalo, Shobha Swaminathan, Sue Ellen Abdalian, Hong‐Van Tieu, José A. Bazan, Ian Frank, Carlos del Rı́o, Aditya H. Gaur, Raphael J. Landovitz, Jesse L. Clark, Richard Novák, Rachel M. Presti, Roy M. Gulick, Rachel M. Presti, Roy M. Gulick